MedTrace Logo

GARM II: A Study on the Genetics of Age-related Maculopathy

NCT01115387 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 603

Last updated 2023-11-07

No results posted yet for this study

Summary

The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of adults (49 to 65 years old). The purpose of this study is to identify the hereditary and exposure risk factors that lead to the development of ARM (Age related maculopathy).

Participants will communicate with the research staff through a protected and confidential website and use this website to complete a number of questionnaires during the course of the study (see below). For genetic analyses, the participants will mail in easily self-collected saliva samples in special containers. Eye photographs and eye health records are sent to the research center from local sources through the Internet. Individuals are not expected to come to UCLA in order to participate.

https://jseiclinres.jsei.ucla.edu/garm/

Participants will be expected to answer questionnaires or surveys about medical history, ocular history and visual symptoms, family history, smoking, dietary supplements and light exposure.

Conditions

  • Age-related Macular Degeneration
  • Age-related Maculopathy

Interventions

OTHER

Observational-1

Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures. Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing.

OTHER

Observational-2

A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM. No prospective retina photographs but ongoing follow-up for reported changes in ARM status. A saliva or blood sample for genetic testing.

Sponsors & Collaborators

  • Jules Stein Eye Institute

    collaborator OTHER

  • University of Pittsburgh

    collaborator OTHER

  • National Eye Institute (NEI)

    collaborator NIH

  • University of California, Los Angeles

    lead OTHER

Principal Investigators

  • Michael B Gorin, MD, PhD · Jules Stein Eye Institute, UCLA

Eligibility

Min Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-06
Primary Completion
2016-02-29
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01115387 on ClinicalTrials.gov